Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced a significant decline recently despite a substantial increase in its price year-to-date, indicating potential volatility in the market [1][2]. - As of September 23, 泰恩康's stock price was 33.84 yuan per share, with a market capitalization of 14.399 billion yuan [1]. - The company has seen a year-to-date stock price increase of 128.79%, but it has declined by 12.42% over the last five trading days [1]. Group 2 - 泰恩康's main business segments include pharmaceutical agency (65.16%), pharmaceutical manufacturing (31.70%), and pharmaceutical technology services (2.97%) [1]. - As of June 30, the number of shareholders decreased by 33.05% to 10,900, while the average circulating shares per person increased by 49.36% to 27,747 shares [2]. - For the first half of 2025, 泰恩康 reported a revenue of 347 million yuan, a year-on-year decrease of 12.23%, and a net profit of 37.084 million yuan, down 56.75% year-on-year [2]. Group 3 - Since its A-share listing, 泰恩康 has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].
泰恩康跌2.03%，成交额1.14亿元，主力资金净流出1306.31万元